Jinghai Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jinghai Chen has a total of 277 co-authors. Here are the top co-authors by number of shared publications:
Feng Gao
Department of Cardiology of Second Affiliated Hospital, State Key Laboratory of Transvascular Implantation Devices, Heart Regeneration and Repair Key Laboratory of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China
12 shared publications- Jian-An Wang
Cardiovascular Internal Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
11 shared publications Feng Zhang
Department of Cardiology of Second Affiliated Hospital, State Key Laboratory of Transvascular Implantation Devices, Heart Regeneration and Repair Key Laboratory of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China
10 shared publications- Da-Zhi Wang
Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, USA
9 shared publications Tian Liang
Department of Cardiology of Second Affiliated Hospital, State Key Laboratory of Transvascular Implantation Devices, Heart Regeneration and Repair Key Laboratory of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China
9 shared publicationsXinyang Hu
Department of Cardiology, State Key Laboratory of Transvascular Implantation Devices, Heart Regeneration and Repair Key Laboratory of Zhejiang Province, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China; Transvascular Implantation Devices Research Institute (TIDRI), Hangzhou 310053, China
9 shared publications
Latest Publications
- 5 August 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (8) , 705-724
Mechanical unloading promotes adult cardiomyocyte proliferation through epicardial NRG1–ERBB4 signaling
- 5 August 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (8) , 705-724
Mechanical unloading promotes adult cardiomyocyte proliferation through epicardial NRG1–ERBB4 signaling
- Open Access
- 17 May 2026
- Published by Elsevier in Journal of Advanced Research
PRR33 protects against cardiac hypertrophy by regulating myocyte cytoskeleton remodeling
- 17 May 2026
- Published by Elsevier in Journal of Advanced Research
Open AccessPRR33 protects against cardiac hypertrophy by regulating myocyte cytoskeleton remodeling
- 27 March 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (7)
TMC6 Is a Novel Therapeutic Target for Pathogenic Cardiac Hypertrophy
BACKGROUND: Pathogenic cardiac hypertrophy, often driven by mechanical stress, is a leading cause of heart failure. However, effective therapeutic targets remain limited. TMC6 (transmembrane channel-like protein 6) is abundant in healthy myocardium but downregulated in hypertrophic hearts; its role in cardiac hypertrophy remains undefined. METHODS: We combined cardiac-specific Tmc6 knockout mice subjected to transverse aortic constriction surgery, neonatal rat ventricular myocytes, and CRISPR/Cas9-edited human pluripotent stem cell-derived cardiomyocytes to assess hypertrophy and signaling readouts. Subcellular localization, protein–protein interaction, and competitive peptide assays were used to dissect the mechanism. Adeno-associated virus serotype 9 (AAV9)-cTnT (cardiac troponin T)-TMC6 was used for in vivo rescue. RESULTS: TMC6 deficiency increased cardiomyocyte size, fetal gene expression, and adverse remodeling in vivo and in vitro, whereas TMC6 overexpression blunted hypertrophic responses. Full-length TMC6 localized to the endoplasmic reticulum and bound CIB1 (calcium and integrin-binding protein 1) to sequester it in the endoplasmic reticulum, limiting CIB1 access to sarcolemmal Ca 2+ microdomains required to scaffold calcineurin and activate NFAT (nuclear factor of activated T cells). A cell-permeable TMC6 161–180 peptide competitively displaced CIB1 from TMC6 and augmented hypertrophy in wild-type but not Tmc6 knockout cardiomyocytes, indicating a dominant-negative mechanism. Therapeutically, AAV9-cTnT-TMC6 restored TMC6–CIB1 engagement, suppressed calcineurin/NFAT readouts, and improved function after pressure overload. CONCLUSIONS: TMC6 is an endogenous brake on pathological hypertrophy that restrains CIB1-calcineurin/NFAT signaling via endoplasmic reticulum sequestration of CIB1. Restoring full-length TMC6 mitigates pressure-overload remodeling, nominating the TMC6–CIB1 axis as a therapeutic target.
- 27 March 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (7)
TMC6 Is a Novel Therapeutic Target for Pathogenic Cardiac Hypertrophy
BACKGROUND: Pathogenic cardiac hypertrophy, often driven by mechanical stress, is a leading cause of heart failure. However, effective therapeutic targets remain limited. TMC6 (transmembrane channel-like protein 6) is abundant in healthy myocardium but downregulated in hypertrophic hearts; its role in cardiac hypertrophy remains undefined. METHODS: We combined cardiac-specific Tmc6 knockout mice subjected to transverse aortic constriction surgery, neonatal rat ventricular myocytes, and CRISPR/Cas9-edited human pluripotent stem cell-derived cardiomyocytes to assess hypertrophy and signaling readouts. Subcellular localization, protein–protein interaction, and competitive peptide assays were used to dissect the mechanism. Adeno-associated virus serotype 9 (AAV9)-cTnT (cardiac troponin T)-TMC6 was used for in vivo rescue. RESULTS: TMC6 deficiency increased cardiomyocyte size, fetal gene expression, and adverse remodeling in vivo and in vitro, whereas TMC6 overexpression blunted hypertrophic responses. Full-length TMC6 localized to the endoplasmic reticulum and bound CIB1 (calcium and integrin-binding protein 1) to sequester it in the endoplasmic reticulum, limiting CIB1 access to sarcolemmal Ca 2+ microdomains required to scaffold calcineurin and activate NFAT (nuclear factor of activated T cells). A cell-permeable TMC6 161–180 peptide competitively displaced CIB1 from TMC6 and augmented hypertrophy in wild-type but not Tmc6 knockout cardiomyocytes, indicating a dominant-negative mechanism. Therapeutically, AAV9-cTnT-TMC6 restored TMC6–CIB1 engagement, suppressed calcineurin/NFAT readouts, and improved function after pressure overload. CONCLUSIONS: TMC6 is an endogenous brake on pathological hypertrophy that restrains CIB1-calcineurin/NFAT signaling via endoplasmic reticulum sequestration of CIB1. Restoring full-length TMC6 mitigates pressure-overload remodeling, nominating the TMC6–CIB1 axis as a therapeutic target.
- Open Access
- 10 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Cardiomyocyte lncRNA Cpat maintains cardiac homeostasis and mitochondria function by targeting citrate synthase acetylation
Myocardial energy metabolism disorders are essential pathophysiology in sepsis-associated myocardial injury. Yet, the underlying mechanisms involving impaired mitochondrial respiratory function upon myocardial injury remain poorly understood. Here we identify an unannotated and cardiomyocyte-enriched long non-coding RNA, Cpat (cardiac-protector-associated transcript), that plays an important role in regulating the dynamics of cardiomyocyte mitochondrial tricarboxylic acid (TCA) cycle. Cpat is essential to the mitochondrial respiratory function by targeting key metabolic enzymes and modulating TCA cycle flux. Specifically, Cpat enhances the association of TCA cycle core components malate dehydrogenase (MDH2), citrate synthase (CS), and aconitase (ACO2). Acetyltransferase general control non-repressed protein-5 (GCN5) acetylates CS and destabilizes the MDH2-CS-ACO2 complex formation. Cpat inhibits this GCN5 activity and facilitates MDH2-CS-ACO2 complex formation and TCA cycle flux. We reveal that Cpat-mediated mitochondrial metabolic homeostasis is vital in mitigating myocardial injury in sepsis-induced cardiomyopathy, positioning Cpat as a promising therapeutic target for preserving myocardial cellular metabolism and function.
- 10 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Open AccessCardiomyocyte lncRNA Cpat maintains cardiac homeostasis and mitochondria function by targeting citrate synthase acetylation
Myocardial energy metabolism disorders are essential pathophysiology in sepsis-associated myocardial injury. Yet, the underlying mechanisms involving impaired mitochondrial respiratory function upon myocardial injury remain poorly understood. Here we identify an unannotated and cardiomyocyte-enriched long non-coding RNA, Cpat (cardiac-protector-associated transcript), that plays an important role in regulating the dynamics of cardiomyocyte mitochondrial tricarboxylic acid (TCA) cycle. Cpat is essential to the mitochondrial respiratory function by targeting key metabolic enzymes and modulating TCA cycle flux. Specifically, Cpat enhances the association of TCA cycle core components malate dehydrogenase (MDH2), citrate synthase (CS), and aconitase (ACO2). Acetyltransferase general control non-repressed protein-5 (GCN5) acetylates CS and destabilizes the MDH2-CS-ACO2 complex formation. Cpat inhibits this GCN5 activity and facilitates MDH2-CS-ACO2 complex formation and TCA cycle flux. We reveal that Cpat-mediated mitochondrial metabolic homeostasis is vital in mitigating myocardial injury in sepsis-induced cardiomyopathy, positioning Cpat as a promising therapeutic target for preserving myocardial cellular metabolism and function.
- 10 June 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (23) , 1667-1685
FMO2 Prevents Pathological Cardiac Hypertrophy by Maintaining the ER-Mitochondria Association Through Interaction With IP3R2-Grp75-VDAC1
BACKGROUND: Cardiac hypertrophy, as an important pathological change, contributes to heart failure. Recent studies indicate that the mitochondria-associated endoplasmic reticulum membranes (MAMs) play key roles in this pathological process. However, the molecular mechanism remains unclear. This study aims to elucidate the effects and mechanisms of MAM-resident FMO2 (flavin-containing monooxygenase 2) in cardiac hypertrophy and heart failure. METHODS: We performed bulk RNA-sequencing analysis using heart tissue from patients with cardiac hypertrophy and carried out MAM-targeted mass spectrometry analysis using heart tissue from a mouse model of pathological cardiac hypertrophy. In vitro cell culture using neonatal rat cardiomyocytes was used to study how MAMs formation affected cardiomyocyte functions. By generating different genetic mouse models combined with using adeno-associated virus 9 under the cardiac troponin T promoter techniques, we further investigated and confirmed the effects of MAM structure changes on cardiac hypertrophy. RESULTS: We detected an unexpected component of MAMs structure, which was the FMO2, an endoplasmic reticulum–resident protein. FMO2 levels decreased during pathological cardiac hypertrophy. The deletion and overexpression of FMO2 can either worsen or prevent the pathological heart failure progression in vivo, respectively. Our data further demonstrated that FMO2 localizes to MAM structure, where it binds to inositol 1,4,5-trisphosphate type 2 receptor (IP3R2) as a component of the IP3R2–Grp75 (glucose-regulated protein 75)–VDAC1 (voltage-dependent anion channel protein 1) complex, maintaining endoplasmic reticulum–mitochondria contact and regulating mitochondrial Ca 2+ signaling for bioenergetics. Last, we showed that a synthetic peptide-enhancing endoplasmic reticulum–mitochondria contact promoted Ca 2+ transfer and prevented pathological cardiac hypertrophy. CONCLUSIONS: Our findings reveal a key role of FMO2 in myocardial hypertrophy and that FMO2 plays a pivotal role in maintaining MAM structure and function, which may represent a novel mechanism and therapeutic target for cardiac hypertrophy and heart failure.
- 10 June 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (23) , 1667-1685
FMO2 Prevents Pathological Cardiac Hypertrophy by Maintaining the ER-Mitochondria Association Through Interaction With IP3R2-Grp75-VDAC1
BACKGROUND: Cardiac hypertrophy, as an important pathological change, contributes to heart failure. Recent studies indicate that the mitochondria-associated endoplasmic reticulum membranes (MAMs) play key roles in this pathological process. However, the molecular mechanism remains unclear. This study aims to elucidate the effects and mechanisms of MAM-resident FMO2 (flavin-containing monooxygenase 2) in cardiac hypertrophy and heart failure. METHODS: We performed bulk RNA-sequencing analysis using heart tissue from patients with cardiac hypertrophy and carried out MAM-targeted mass spectrometry analysis using heart tissue from a mouse model of pathological cardiac hypertrophy. In vitro cell culture using neonatal rat cardiomyocytes was used to study how MAMs formation affected cardiomyocyte functions. By generating different genetic mouse models combined with using adeno-associated virus 9 under the cardiac troponin T promoter techniques, we further investigated and confirmed the effects of MAM structure changes on cardiac hypertrophy. RESULTS: We detected an unexpected component of MAMs structure, which was the FMO2, an endoplasmic reticulum–resident protein. FMO2 levels decreased during pathological cardiac hypertrophy. The deletion and overexpression of FMO2 can either worsen or prevent the pathological heart failure progression in vivo, respectively. Our data further demonstrated that FMO2 localizes to MAM structure, where it binds to inositol 1,4,5-trisphosphate type 2 receptor (IP3R2) as a component of the IP3R2–Grp75 (glucose-regulated protein 75)–VDAC1 (voltage-dependent anion channel protein 1) complex, maintaining endoplasmic reticulum–mitochondria contact and regulating mitochondrial Ca 2+ signaling for bioenergetics. Last, we showed that a synthetic peptide-enhancing endoplasmic reticulum–mitochondria contact promoted Ca 2+ transfer and prevented pathological cardiac hypertrophy. CONCLUSIONS: Our findings reveal a key role of FMO2 in myocardial hypertrophy and that FMO2 plays a pivotal role in maintaining MAM structure and function, which may represent a novel mechanism and therapeutic target for cardiac hypertrophy and heart failure.
- Open Access
- 1 June 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 48, 43-54
MiR-19-loaded oxidative stress-relief microgels with immunomodulatory and regeneration functions to reduce cardiac remodeling after myocardial infarction
Regeneration therapeutic strategy by microRNAs for boosting cardiomyocyte proliferation in treating myocardial infarction (MI) has the challenges of efficient delivery, and toxicity and risk of sudden death. Herein, oxidative stress-relief microgels were developed for miR-19a/b delivery, modulation of inflammatory tissue microenvironment, promotion of cardiomyocyte proliferation, and maintenance of heart function post MI. The cholesterol-modified miR-19a/b was encapsulated into the cavity of β-cyclodextrin in selenoketal-containing microgels. The microgels could effectively scavenge typical reactive oxygen species (ROS), and down-regulate the intracellular ROS level and the levels of typical inflammatory factors. The microgels could improve the acute inflammatory microenvironment for better cardiomyocyte survival and cellular uptake of miR-19a/b, leading to significant promotion of cardiomyocyte proliferation in vivo. In the rat and minipig models of MI, the microgels most effectively inhibited the acute inflammatory response and reduced the cardiomyocytes apoptosis, resulting in a significant improvement of cardiac function and restriction of pathological remodeling post MI, and thereby best heart function revealed by echocardiography and histological analysis.
- 1 June 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 48, 43-54
Open AccessMiR-19-loaded oxidative stress-relief microgels with immunomodulatory and regeneration functions to reduce cardiac remodeling after myocardial infarction
Regeneration therapeutic strategy by microRNAs for boosting cardiomyocyte proliferation in treating myocardial infarction (MI) has the challenges of efficient delivery, and toxicity and risk of sudden death. Herein, oxidative stress-relief microgels were developed for miR-19a/b delivery, modulation of inflammatory tissue microenvironment, promotion of cardiomyocyte proliferation, and maintenance of heart function post MI. The cholesterol-modified miR-19a/b was encapsulated into the cavity of β-cyclodextrin in selenoketal-containing microgels. The microgels could effectively scavenge typical reactive oxygen species (ROS), and down-regulate the intracellular ROS level and the levels of typical inflammatory factors. The microgels could improve the acute inflammatory microenvironment for better cardiomyocyte survival and cellular uptake of miR-19a/b, leading to significant promotion of cardiomyocyte proliferation in vivo. In the rat and minipig models of MI, the microgels most effectively inhibited the acute inflammatory response and reduced the cardiomyocytes apoptosis, resulting in a significant improvement of cardiac function and restriction of pathological remodeling post MI, and thereby best heart function revealed by echocardiography and histological analysis.
- Open Access
- 7 April 2025
- Published by Wiley in Advanced Science
- Vol. 12 (23) , e2416478
Cardiomyocyte‐Enriched USP20 Ameliorates Pathological Cardiac Hypertrophy by Targeting STAT3 Deubiquitination
Although pathological cardiac hypertrophy is a key driver of heart failure, the underlying mechanisms remain incompletely elucidated. This study investigates the role and mechanism of deubiquitinating enzyme (DUB) ubiquitin‐specific protease 20 (USP20) in cardiac hypertrophy. Transcriptomic profiling of hypertrophic hearts shows significant alterations in the expression of DUBs, including a remarkable downregulation of USP20. USP20 is predominantly expressed in cardiomyocytes. Co‐immunoprecipitation (Co‐IP) followed by liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) is used to identify USP20 substrates. Cleavage Under Targets and Tagmentation assay (CUT&Tag) sequencing is employed to identify downstream targets of signal transducer and activator of transcription 3 (STAT3). Functionally, USP20 deficiency exacerbates cardiac hypertrophy induced by either angiotensin II (Ang II) or transverse aortic constriction (TAC), whereas USP20 overexpression alleviates hypertrophic responses. Mechanistically, USP20 deubiquitinates STAT3 by removing K63‐linked ubiquitin chains at K177 via its H645 active site, reducing STAT3 phosphorylation and nuclear translocation. This inhibites STAT3's transcriptional activity at coactivator‐associated arginine methyltransfer ( Carm1) promoter, leading to upregulated CARM1 expression and mitigated hypertrophy. Importantly, the STAT3 inhibitor Stattic confirms STAT3 serves as a key substrate mediating the cardiac protective effects of USP20. These findings unveil a novel USP20/STAT3/CARM1 axis in cardiomyocytes and reveal its therapeutic potential for cardiac hypertrophy.
- 7 April 2025
- Published by Wiley in Advanced Science
- Vol. 12 (23) , e2416478
Open AccessCardiomyocyte‐Enriched USP20 Ameliorates Pathological Cardiac Hypertrophy by Targeting STAT3 Deubiquitination
Although pathological cardiac hypertrophy is a key driver of heart failure, the underlying mechanisms remain incompletely elucidated. This study investigates the role and mechanism of deubiquitinating enzyme (DUB) ubiquitin‐specific protease 20 (USP20) in cardiac hypertrophy. Transcriptomic profiling of hypertrophic hearts shows significant alterations in the expression of DUBs, including a remarkable downregulation of USP20. USP20 is predominantly expressed in cardiomyocytes. Co‐immunoprecipitation (Co‐IP) followed by liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) is used to identify USP20 substrates. Cleavage Under Targets and Tagmentation assay (CUT&Tag) sequencing is employed to identify downstream targets of signal transducer and activator of transcription 3 (STAT3). Functionally, USP20 deficiency exacerbates cardiac hypertrophy induced by either angiotensin II (Ang II) or transverse aortic constriction (TAC), whereas USP20 overexpression alleviates hypertrophic responses. Mechanistically, USP20 deubiquitinates STAT3 by removing K63‐linked ubiquitin chains at K177 via its H645 active site, reducing STAT3 phosphorylation and nuclear translocation. This inhibites STAT3's transcriptional activity at coactivator‐associated arginine methyltransfer ( Carm1) promoter, leading to upregulated CARM1 expression and mitigated hypertrophy. Importantly, the STAT3 inhibitor Stattic confirms STAT3 serves as a key substrate mediating the cardiac protective effects of USP20. These findings unveil a novel USP20/STAT3/CARM1 axis in cardiomyocytes and reveal its therapeutic potential for cardiac hypertrophy.
- Top Cited PapersOpen Access
- 9 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Alleviation of liver fibrosis by inhibiting a non-canonical ATF4-regulated enhancer program in hepatic stellate cells
Liver fibrosis is a critical liver disease that can progress to more severe manifestations, such as cirrhosis, yet no effective targeted therapies are available. Here, we identify that ATF4, a master transcription factor in ER stress response, promotes liver fibrosis by facilitating a stress response-independent epigenetic program in hepatic stellate cells (HSCs). Unlike its canonical role in regulating UPR genes during ER stress, ATF4 activates epithelial-mesenchymal transition (EMT) gene transcription under fibrogenic conditions. HSC-specific depletion of ATF4 suppresses liver fibrosis in vivo. Mechanistically, TGFβ resets ATF4 to orchestrate a unique enhancer program for the transcriptional activation of pro-fibrotic EMT genes. Analysis of human data confirms a strong correlation between HSC ATF4 expression and liver fibrosis progression. Importantly, a small molecule inhibitor targeting ATF4 translation effectively mitigates liver fibrosis. Together, our findings identify a mechanism promoting liver fibrosis and reveal new opportunities for treating this otherwise non-targetable disease.
- 9 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Top Cited PapersOpen AccessAlleviation of liver fibrosis by inhibiting a non-canonical ATF4-regulated enhancer program in hepatic stellate cells
Liver fibrosis is a critical liver disease that can progress to more severe manifestations, such as cirrhosis, yet no effective targeted therapies are available. Here, we identify that ATF4, a master transcription factor in ER stress response, promotes liver fibrosis by facilitating a stress response-independent epigenetic program in hepatic stellate cells (HSCs). Unlike its canonical role in regulating UPR genes during ER stress, ATF4 activates epithelial-mesenchymal transition (EMT) gene transcription under fibrogenic conditions. HSC-specific depletion of ATF4 suppresses liver fibrosis in vivo. Mechanistically, TGFβ resets ATF4 to orchestrate a unique enhancer program for the transcriptional activation of pro-fibrotic EMT genes. Analysis of human data confirms a strong correlation between HSC ATF4 expression and liver fibrosis progression. Importantly, a small molecule inhibitor targeting ATF4 translation effectively mitigates liver fibrosis. Together, our findings identify a mechanism promoting liver fibrosis and reveal new opportunities for treating this otherwise non-targetable disease.
- Open Access
- 25 October 2024
- Published by Springer Nature in Research Square
Cardiomyocyte-enriched USP20 ameliorates pathological cardiac hypertrophy by targeting STAT3-CARM1 axis
Pathological cardiac hypertrophy can lead to heart failure. The molecular mechanisms underlying pathological cardiac hypertrophy remain undefined. This study aimed to examine the role and molecular mechanisms of a deubiquitinating enzyme (DUB), ubiquitin-specific protease 20 (USP20) in cardiac hypertrophy. Hypertrophic hearts were conducted for RNA-sequencing to screen the expression profiles of DUBs. Cardiomyocyte-specific USP20 knockout and overexpression mouse models were generated to explore its function. Co-immunoprecipitation coupled with liquid chromatography-mass spectrometry/mass spectrometry were performed to screen potential USP20 substrates. Cleavage under targets and tagmentation assay with high-throughput sequencing was utilized to identify the potential downstream targets of STAT3. We identified cardiomyocyte-enriched USP20 is downregulated in cardiac hypertrophy. Cardiomyocyte-specific USP20 deficiency exacerbated cardiac hypertrophy induced by Angiotensin II and transverse aortic constriction, whereas cardiomyocyte-specific USP20 overexpression ameliorated the phenotype. We further identified STAT3 is a substrate of USP20 during cardiac hypertrophy through direct binding with DUSP2 domain. Mechanistically, USP20 removes K63 ubiquitin chains from STAT3 at the K177 site via its H645 active site, reducing STAT3 phosphorylation and nuclear translocation. This prevents STAT3 from binding to the coactivator-associated arginine methyltransferase 1 (CARM1) promoter, thereby promoting CARM1 transcription and improving cardiac hypertrophy. Importantly, we discover with STAT3 inhibitor stattic that STAT3 is a key substrate through which USP20 exerts its therapeutic effect on cardiac hypertrophy. These results elucidate a critical role for a novel USP20/STAT3/CARM1 axis in cardiomyocytes and an exciting new avenue study for therapies to treat cardiac hypertrophy.
- 25 October 2024
- Published by Springer Nature in Research Square
Open AccessCardiomyocyte-enriched USP20 ameliorates pathological cardiac hypertrophy by targeting STAT3-CARM1 axis
Pathological cardiac hypertrophy can lead to heart failure. The molecular mechanisms underlying pathological cardiac hypertrophy remain undefined. This study aimed to examine the role and molecular mechanisms of a deubiquitinating enzyme (DUB), ubiquitin-specific protease 20 (USP20) in cardiac hypertrophy. Hypertrophic hearts were conducted for RNA-sequencing to screen the expression profiles of DUBs. Cardiomyocyte-specific USP20 knockout and overexpression mouse models were generated to explore its function. Co-immunoprecipitation coupled with liquid chromatography-mass spectrometry/mass spectrometry were performed to screen potential USP20 substrates. Cleavage under targets and tagmentation assay with high-throughput sequencing was utilized to identify the potential downstream targets of STAT3. We identified cardiomyocyte-enriched USP20 is downregulated in cardiac hypertrophy. Cardiomyocyte-specific USP20 deficiency exacerbated cardiac hypertrophy induced by Angiotensin II and transverse aortic constriction, whereas cardiomyocyte-specific USP20 overexpression ameliorated the phenotype. We further identified STAT3 is a substrate of USP20 during cardiac hypertrophy through direct binding with DUSP2 domain. Mechanistically, USP20 removes K63 ubiquitin chains from STAT3 at the K177 site via its H645 active site, reducing STAT3 phosphorylation and nuclear translocation. This prevents STAT3 from binding to the coactivator-associated arginine methyltransferase 1 (CARM1) promoter, thereby promoting CARM1 transcription and improving cardiac hypertrophy. Importantly, we discover with STAT3 inhibitor stattic that STAT3 is a key substrate through which USP20 exerts its therapeutic effect on cardiac hypertrophy. These results elucidate a critical role for a novel USP20/STAT3/CARM1 axis in cardiomyocytes and an exciting new avenue study for therapies to treat cardiac hypertrophy.
- Open Access
- 21 October 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (24)
Flavin-containing monooxygenase 2 confers cardioprotection in ischemia models through its disulfide bond catalytic activity
Myocardial infarction (MI) is characterized by massive cardiomyocyte (CM) death and cardiac dysfunction, and effective therapies to achieve cardioprotection are greatly needed. Here, we report that flavin-containing monooxygenase 2 (FMO2) levels were markedly increased in CMs in both ex vivo and in vivo models of ischemic injury. Genetic deletion of FMO2 resulted in reduced CM survival and enhanced cardiac dysfunction, whereas CM-specific FMO2 overexpression conferred a protective effect in infarcted rat hearts. Mechanistically, FMO2 inhibited the activation of ER stress–induced apoptotic proteins, including caspase 12 and C/EBP homologous protein (CHOP), by downregulating the unfolded protein response pathway. Furthermore, we identified FMO2 as a chaperone that catalyzes disulfide bond formation in unfolded and misfolded proteins through its GVSG motif. GVSG-mutated FMO2 failed to catalyze disulfide bond formation and lost its protection against ER stress and CM death. Finally, we demonstrated the protective effect of FMO2 in a human induced pluripotent stem cell–derived CM model. Collectively, this study highlights FMO2 as a key modulator of oxidative protein folding in CMs and underscores its therapeutic potential for treating ischemic heart disease.
- 21 October 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (24)
Open AccessFlavin-containing monooxygenase 2 confers cardioprotection in ischemia models through its disulfide bond catalytic activity
Myocardial infarction (MI) is characterized by massive cardiomyocyte (CM) death and cardiac dysfunction, and effective therapies to achieve cardioprotection are greatly needed. Here, we report that flavin-containing monooxygenase 2 (FMO2) levels were markedly increased in CMs in both ex vivo and in vivo models of ischemic injury. Genetic deletion of FMO2 resulted in reduced CM survival and enhanced cardiac dysfunction, whereas CM-specific FMO2 overexpression conferred a protective effect in infarcted rat hearts. Mechanistically, FMO2 inhibited the activation of ER stress–induced apoptotic proteins, including caspase 12 and C/EBP homologous protein (CHOP), by downregulating the unfolded protein response pathway. Furthermore, we identified FMO2 as a chaperone that catalyzes disulfide bond formation in unfolded and misfolded proteins through its GVSG motif. GVSG-mutated FMO2 failed to catalyze disulfide bond formation and lost its protection against ER stress and CM death. Finally, we demonstrated the protective effect of FMO2 in a human induced pluripotent stem cell–derived CM model. Collectively, this study highlights FMO2 as a key modulator of oxidative protein folding in CMs and underscores its therapeutic potential for treating ischemic heart disease.